Guanze Medical Information Industry (Holding) Co., Ltd. (the “Company,” Stock Code: 2427) and FUNDE (HONG KONG) INVESTMENT HOLDINGS CO., LIMITED (“FUNDE HK”) jointly announced the completion of a sale and purchase agreement leading to a mandatory unconditional cash offer for all remaining issued shares of the Company.

FUNDE HK acquired approximately 699,164,575 shares from Meng A Capital Limited (the “Selling Shareholder”), representing around 73.60% of the Company’s total issued share capital. The total consideration amounted to HK$174,791,143.75 at HK$0.25 per share. Following completion, FUNDE HK is required under the Takeovers Code to make a mandatory unconditional cash offer for the remaining 250,835,425 shares at the same price of HK$0.25 per share.

The maximum additional cash consideration payable for full acceptance of the offer stands at approximately HK$62,708,856.25. Immediately before the transaction, neither FUNDE HK nor its ultimate beneficial owners held any shares in the Company. After completion, FUNDE HK became the controlling shareholder with approximately 73.60% of the Company’s total issued share capital.

According to the announcement, FUNDE HK intends to maintain the Company’s listing on the Stock Exchange and take steps to ensure a sufficient public float. The Company’s Independent Board Committee, composed of all three independent non-executive directors, will advise shareholders on the fairness of the offer. The Composite Document, containing full details of the offer and its terms, is expected to be dispatched on or before March 4, 2026.

Trading in the Company’s shares resumed on February 12, 2026, following a temporary halt pending publication of the joint announcement. The Company cautions shareholders and potential investors to exercise prudence when dealing in its shares and to carefully review the forthcoming Composite Document before making any decision regarding acceptance of the offer.